| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P Bischoff, E Koch. [Alpha 2-agonists in anesthesia and intensive medicine]. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS. vol 28. issue 1. 1993-05-10. PMID:8096770. |
more selective for the alpha 2-adrenoceptor than clonidine is dexmedetomidine (1600/1 of alpha 2/alpha 1), a very potent agonist at the alpha 2-adrenoceptor. |
1993-05-10 |
2023-08-12 |
Not clear |
| Y Takano, T L Yaks. Chronic spinal infusion of dexmedetomidine, ST-91 and clonidine: spinal alpha 2 adrenoceptor subtypes and intrinsic activity. The Journal of pharmacology and experimental therapeutics. vol 264. issue 1. 1993-02-23. PMID:8093729. |
chronic spinal infusion of dexmedetomidine, st-91 and clonidine: spinal alpha 2 adrenoceptor subtypes and intrinsic activity. |
1993-02-23 |
2023-08-12 |
rat |
| Y Takano, T L Yaks. Chronic spinal infusion of dexmedetomidine, ST-91 and clonidine: spinal alpha 2 adrenoceptor subtypes and intrinsic activity. The Journal of pharmacology and experimental therapeutics. vol 264. issue 1. 1993-02-23. PMID:8093729. |
infusion of alpha 2 adrenoceptor agonists dexmedetomidine (10 and 3 nmol/hr), clonidine (100 and 30 nmol/hr) and 2-(2,6-diethylphenylamino)-2-imidazoline (st-91) (30 and 10 nmol/hr) were examined in rats. |
1993-02-23 |
2023-08-12 |
rat |
| Y Takano, T L Yaks. Chronic spinal infusion of dexmedetomidine, ST-91 and clonidine: spinal alpha 2 adrenoceptor subtypes and intrinsic activity. The Journal of pharmacology and experimental therapeutics. vol 264. issue 1. 1993-02-23. PMID:8093729. |
previously, we have shown that dexmedetomidine and clonidine act upon spinal alpha 2 adrenoceptor, which appeared distinguishable from that acted upon by st-91. |
1993-02-23 |
2023-08-12 |
rat |
| T Harada, C E Constantino. The effect of alpha 2 agonists and antagonists on the lower urinary tract of the rat. The Journal of urology. vol 149. issue 1. 1993-01-25. PMID:8093264. |
the results show that in an anesthetized preparation, the alpha 2 agonist dexmedetomidine produced inhibitory effects on the volume evoked micturition reflex (vemr) at a dose level of 2.0 micrograms./kg. |
1993-01-25 |
2023-08-12 |
rat |
| C Correa-Sales, C Nacif-Coelho, K Reid, M Maz. Inhibition of adenylate cyclase in the locus coeruleus mediates the hypnotic response to an alpha 2 agonist in the rat. The Journal of pharmacology and experimental therapeutics. vol 263. issue 3. 1993-01-22. PMID:1361568. |
recently, we determined that the transduction mechanism for the hypnotic response to dexmedetomidine, a highly selective alpha 2 agonist, resides in the locus coeruleus (lc) of the rat. |
1993-01-22 |
2023-08-11 |
rat |
| J P Belleville, D S Ward, B C Bloor, M Maz. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology. vol 77. issue 6. 1993-01-21. PMID:1361310. |
dexmedetomidine (dmed) is a highly selective centrally acting alpha 2-adrenergic agonist thought to provide significant sedation without appreciable ventilatory effects. |
1993-01-21 |
2023-08-11 |
human |
| M Hong, B Milne, C Loomis, K Jhamanda. Stereoselective effects of central alpha 2-adrenergic agonist medetomidine on in vivo catechol activity in the rat rostral ventrolateral medulla (RVLM). Brain research. vol 592. issue 1-2. 1993-01-06. PMID:1360311. |
the depressant effects of dexmedetomidine on catechol oxidation current were reversed by the selective alpha 2-adrenoceptor antagonist atipamezole (2 micrograms, i.c.v. |
1993-01-06 |
2023-08-11 |
rat |
| C Correa-Sales, K Reid, M Maz. Pertussis toxin-mediated ribosylation of G proteins blocks the hypnotic response to an alpha 2-agonist in the locus coeruleus of the rat. Pharmacology, biochemistry, and behavior. vol 43. issue 3. 1992-12-30. PMID:1360160. |
recently, we determined that the transduction mechanism for the hypnotic response to dexmedetomidine, a highly selective alpha 2-agonist, is located in the locus coeruleus (lc) of the rat. |
1992-12-30 |
2023-08-11 |
rat |
| H Scheinin, S Karhuvaara, K T Olkkola, A Kallio, M Anttila, L Vuorilehto, M Scheini. Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. Clinical pharmacology and therapeutics. vol 52. issue 5. 1992-12-22. PMID:1358496. |
the pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine--a novel alpha 2-adrenergic receptor agonist under development for preanesthetic use--were studied in healthy male volunteers. |
1992-12-22 |
2023-08-11 |
human |
| H Scheinin, S Karhuvaara, K T Olkkola, A Kallio, M Anttila, L Vuorilehto, M Scheini. Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. Clinical pharmacology and therapeutics. vol 52. issue 5. 1992-12-22. PMID:1358496. |
the pharmacodynamic-pharmacokinetic profile of intramuscular dexmedetomidine may be suited to the proposed preanesthetic clinical use of this alpha 2-agonist. |
1992-12-22 |
2023-08-11 |
human |
| Z Zhao, W E Code, L Hert. Dexmedetomidine, a potent and highly specific alpha 2 agonist, evokes cytosolic calcium surge in astrocytes but not in neurons. Neuropharmacology. vol 31. issue 10. 1992-12-17. PMID:1359438. |
dexmedetomidine, a potent and highly specific alpha 2 agonist, evokes cytosolic calcium surge in astrocytes but not in neurons. |
1992-12-17 |
2023-08-11 |
Not clear |
| Z Zhao, W E Code, L Hert. Dexmedetomidine, a potent and highly specific alpha 2 agonist, evokes cytosolic calcium surge in astrocytes but not in neurons. Neuropharmacology. vol 31. issue 10. 1992-12-17. PMID:1359438. |
dexmedetomidine is an extremely potent alpha 2 adrenoceptor agonist which can reduce anaesthetic requirements by up to 90%. |
1992-12-17 |
2023-08-11 |
Not clear |
| M G Coughlan, J G Lee, Z J Bosnjak, W T Schmeling, J P Kampine, D C Warltie. Direct coronary and cerebral vascular responses to dexmedetomidine. Significance of endogenous nitric oxide synthesis. Anesthesiology. vol 77. issue 5. 1992-12-03. PMID:1359812. |
dexmedetomidine activates alpha 2-adrenergic receptors in the central nervous system and in the peripheral vasculature. |
1992-12-03 |
2023-08-11 |
Not clear |
| M G Coughlan, J G Lee, Z J Bosnjak, W T Schmeling, J P Kampine, D C Warltie. Direct coronary and cerebral vascular responses to dexmedetomidine. Significance of endogenous nitric oxide synthesis. Anesthesiology. vol 77. issue 5. 1992-12-03. PMID:1359812. |
in vivo dexmedetomidine has been found to cause alterations in coronary and cerebral blood flows and arterial pressure by stimulation of vascular smooth muscle alpha 2 receptors. |
1992-12-03 |
2023-08-11 |
Not clear |
| M G Coughlan, J G Lee, Z J Bosnjak, W T Schmeling, J P Kampine, D C Warltie. Direct coronary and cerebral vascular responses to dexmedetomidine. Significance of endogenous nitric oxide synthesis. Anesthesiology. vol 77. issue 5. 1992-12-03. PMID:1359812. |
the selective alpha 2-adrenergic antagonist atipamezole (10(-4) m) abolished the response to low but not high concentrations of dexmedetomidine in middle cerebral arteries, proximal coronary arteries, and coronary collateral vessels. |
1992-12-03 |
2023-08-11 |
Not clear |
| Y Takano, M Takano, T L Yaks. The effect of intrathecally administered imiloxan and WB4101: possible role of alpha 2-adrenoceptor subtypes in the spinal cord. European journal of pharmacology. vol 219. issue 3. 1992-11-27. PMID:1358645. |
to define the antagonist pharmacology of spinal antinociceptive effects of alpha 2-adrenoceptor agonists, the ability of wb4101 (2-(2,6-dimethoxyphenoxyethyl)-aminomethyl-1,4-benzodioxane) and imiloxan to antagonize the effect of spinal st-91 (2-[2,6-diethylphenylamino]-2-imidazoline), clonidine and dexmedetomidine was examined. |
1992-11-27 |
2023-08-11 |
Not clear |
| Y Takano, M Takano, T L Yaks. The effect of intrathecally administered imiloxan and WB4101: possible role of alpha 2-adrenoceptor subtypes in the spinal cord. European journal of pharmacology. vol 219. issue 3. 1992-11-27. PMID:1358645. |
it is hypothesized that the alpha 2 adrenoceptor subtype alpha 2a is involved in the antinociception of spinal clonidine and dexmedetomidine, and alpha 2b is involved in that of st-91. |
1992-11-27 |
2023-08-11 |
Not clear |
| M Salonen, E S Onaivi, M Maz. Dexmedetomidine synergism with midazolam in the elevated plus-maze test in rats. Psychopharmacology. vol 108. issue 1-2. 1992-11-25. PMID:1357706. |
the anxiolytic profile of dexmedetomidine, a novel, highly-selective alpha 2-adrenergic agonist, was examined in rats in the elevated plus-maze test when administered either alone or in combination with the benzodiazepine agonist midazolam. |
1992-11-25 |
2023-08-11 |
rat |
| M Salonen, E S Onaivi, M Maz. Dexmedetomidine synergism with midazolam in the elevated plus-maze test in rats. Psychopharmacology. vol 108. issue 1-2. 1992-11-25. PMID:1357706. |
this heterergic interaction of dexmedetomidine on midazolam's anxiolytic-like profile was dose-dependently blocked by pretreatment with an alpha 2-adrenergic antagonist, atipamezole, 10-50 micrograms/kg, and a benzodiazepine antagonist flumazenil, 1.0 and 10 mg/kg, but not by the alpha 1-adrenergic antagonist, prazosin, 0.1-10 mg/kg. |
1992-11-25 |
2023-08-11 |
rat |